Volume 5, Issue 3, September 2019, Page: 24-26
Intravitreal Injections of Steroids
Emad Selim, Retinal Unit, Eye Surgery Consultant, London, United Kingdom
Received: Mar. 5, 2019;       Accepted: Apr. 25, 2019;       Published: Oct. 17, 2019
DOI: 10.11648/j.bs.20190503.11      View  43      Downloads  12
Abstract
Intravitreal injection of steroid was first introduced to prevent inflammatory reaction following retinal detachment surgery. Since then it has been use for different condition with inflammatory process at the back of the eye. However, the side effects of steroids in general made their use limited specially with the last few years introduction anti-endothelial vascular growth factor injection.
Keywords
Steroids, Intravitreal, Anti-endothelial, Growth Factor, Uveitis, Cystoid, Macular, Edema
To cite this article
Emad Selim, Intravitreal Injections of Steroids, Biomedical Sciences. Vol. 5, No. 3, 2019, pp. 24-26. doi: 10.11648/j.bs.20190503.11
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Machemer R, Sugita G, and Tano Y: Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 1979; 77: pp. 171-180.
[2]
Lewis GP, Charteris DG, Sethi CS, et al: Animal models of retinal detachment and reattachment: identifying cellular events that may affect visual recovery. Eye 2002; 16: pp. 375-387.
[3]
Benson SE, Grigoropoulos V, Schlottmann PG, et al: Analysis of the macula with optical coherence tomography after successful surgery for proliferative vitreoretinopathy. Arch Ophthalmol 2005; 123: pp. 1651-1656.
[4]
Chung EJ, Lee H, and Koh HJ: Arteriovenous crossing sheathotomy versus intravitreal triamcinolone acetonide injection for treatment of macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008; 246: pp. 967-974.
[5]
Lam HD, Lahey JM, Kearney JJ, et al: Young patients with branch retinal vein occlusion: a review of 60 cases. Retina 2010; 30: pp. 1520-1523.
[6]
Roesel M., Gutfleisch M., Heinz C., et al: Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. Ophthalmic Res 2009; 42: pp. 81-86.
[7]
Williams G.A., Haller J.A., Kuppermann B.D., et al: Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009; 147: pp. 1048-1054.
[8]
Dong Z., Namba K., Kitaichi N., et al: Efficacy and complications of intravitreal injection of triamcinolone acetonide for refractory cystoid macular edema associated with intraocular inflammation. Jpn J Ophthalmol 2008; 52: pp. 374-379.
[9]
Scott IU, Ip MS, VanVeldhuisen PC, et al: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127: pp. 1115-1127.
[10]
Hikichi T, Higuchi M, Matsushita T, et al: Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2014; 98: pp. 195-199.
Browse journals by subject